"We are committed to creating the future of oncology by developing innovative therapies that address unmet medical needs"
Ability Pharmaceuticals
ABOUT
"We are committed to creating the future of oncology by developing innovative therapies that address unmet medical needs"
Ability Pharmaceuticals
LATEST NEWS
News
AbilityPharma Announces FDA Approval of Phase 1/2 Trial of ABTL0812 for Patients with Advanced Metastatic Pancreatic Cancer + infoNews
AbilityPharma Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer + infoNews
Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + infoNews
Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + infoNews
Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + infoNews
Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + infoNews
Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients + infoNews
Ability Pharmaceuticals Enters into a Licensing Agreement with SciClone Pharmaceuticals for the Novel Anticancer Agent ABTL0812 for the China Market. + info
Carretera antiga Amer nº 10
17007 • Girona
T. 972 909 999
E. info@neorgsite.com
http://www.neorgsite.com